NUFYMCO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NUFYMCO (NUFYMCO).
NUFYMCO is a lipid-regulating agent. Its mechanism involves activation of peroxisome proliferator-activated receptor alpha (PPARα), leading to increased lipolysis and elimination of triglyceride-rich particles from plasma, and reduced VLDL production.
| Metabolism | Hepatic via glucuronidation and oxidation (CYP450 minimally involved). Excreted primarily in urine as glucuronide conjugate. |
| Excretion | Renal (60-70% as unchanged drug), biliary/fecal (20-30% as metabolites and unchanged drug) |
| Half-life | Terminal elimination half-life is 12-15 hours in healthy adults, allowing twice-daily dosing; prolonged to 24-36 hours in moderate renal impairment |
| Protein binding | Primarily albumin; 95-98% bound |
| Volume of Distribution | 0.45 L/kg, indicating distribution primarily into extracellular fluid and some tissue binding |
| Bioavailability | Oral: 75-85% (first-pass metabolism limited); no other non-intravenous routes available |
| Onset of Action | Oral: 2-4 hours; Intravenous: 15-30 minutes |
| Duration of Action | Oral: 12-24 hours (dose-dependent); Intravenous: 6-12 hours (supporting twice-daily dosing for most indications) |
NUFYMCO is a proprietary combination product; standard adult dosing is one capsule (25 mg bempedoic acid/20 mg ezetimibe) orally once daily.
| Dosage form | INJECTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73m2). Not recommended in severe renal impairment (eGFR <30 mL/min/1.73m2) or end-stage renal disease due to limited data. |
| Liver impairment | Contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh class B or C). Use with caution in mild hepatic impairment (Child-Pugh class A); no dose adjustment recommended but monitor liver function. |
| Pediatric use | Safety and efficacy in pediatric patients (<18 years) have not been established; no recommended dosing available. |
| Geriatric use | No specific dose adjustment required in elderly patients (≥65 years), but monitor renal function and consider age-related decline in renal function; initiate at the standard dose with careful observation for adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NUFYMCO (NUFYMCO).
| Breastfeeding | No human data; M/P ratio unknown. Excretion into breast milk likely due to molecular weight <500 Da. Use caution; consider alternative therapies or monitor infant for adverse effects. |
| Teratogenic Risk | Pregnancy Category N. No human data available. In animal studies, fetal weight reduction and increased skeletal variations observed at maternal toxic doses. First trimester: theoretical risk based on animal data; avoid unless benefit outweighs risk. Second and third trimesters: monitor fetal growth; risk of oligohydramnios or fetal renal impairment unknown. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Severe renal impairment (eGFR < 30 mL/min/1.73 m²), severe hepatic disease (including primary biliary cirrhosis), known hypersensitivity to any component.
| Precautions | Hepatotoxicity (monitor LFTs), cholelithiasis, myopathy (especially with statins), thromboembolism (in hypercoagulable states), renal impairment (adjust dose). |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal renal function, hepatic function, and blood pressure every 4 weeks. Perform fetal ultrasound for growth assessment and amniotic fluid volume every 4 weeks from 20 weeks gestation. Monitor for signs of preeclampsia. |
| Fertility Effects | No human studies. Animal studies show no impairment of fertility at clinically relevant doses. Theoretical risk of hormonal disruption due to metabolism; advise counseling for patients planning pregnancy. |